Methotrexate Effective in Subcutaneous Psoriasis
(MedPage Today) -- Over 40% of patients achieved PASI 75 response in 16-week trial
Condition: Psoriasis Interventions: Drug: ABBV-157; Drug: Placebo for ABBV-157 Sponsor: AbbVie Not yet recruiting
Authors: Zhang Y, Guo D, Deng H, Li H, Chen Y, Xiao Q, Wu M, Xu R, Li B, Li F PMID: 31001969 [PubMed - in process]
Authors: De Simone C, Caldarola G, Moretta G, Piscitelli L, Ricceri F, Prignano F Abstract Psoriasis affects 2-4% of the world's population, with no difference between men and women and 70% of patients experiencing disease onset before the age of 40, which coincides with the reproductive years. Few data are available from literature on impact of psoriasis on fertility, course and outcome of pregnancy and risk associated with treatments. Recent studies on other immune-mediated inflammatory diseases, among which psoriasis is also included, indicate that rheumatoid arthritis and inflammatory bowel diseases can impact ...
Abstract Aim: To determine the cardiovascular risk and the concordance between the different scores in people with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Methods: Observational descriptive study of prevalence. Performed in the Rheumatology Service and the Clinical Epidemiology and Biostatistics Unit of the University Hospital Complex of A Coruña (Spain). Patients diagnosed with RA or PsA, older than 18 years of age were included. Measurements: sociodemographic, anthropometric variables of the disease, comorbidity, cardiovascular risk, and therapeutic management. Results: 1...
CONCLUSION: Lp-PLA2 assay might be helpful in assessment of the risk of cardiometabolic comorbidities development especially in patients with severe psoriasis and obesity. PMID: 30998429 [PubMed - as supplied by publisher]
Authors: Dattola A, Manfreda V, Esposito M, Bianchi L, Giunta A PMID: 30998424 [PubMed - as supplied by publisher]
Authors: Dalamaga M, Papadavid E PMID: 31002541 [PubMed - as supplied by publisher]
This study aimed to explore the role and regulation mechanism of lysophosphatidic acid (LPA) in the development of psoriasis. Blood and skin samples of psoriasis patients and healthy volunteers were collected. The plasma LPA content was detected by ELISA. The expression of LPA receptor (LPAR) in skin was detected by IHC. After treatment of LPA to keratinocytes: MTS assay and RT-PCR were used to detect the cellular activity and the expression of psoriasis-related molecules respectively. IMQ was used to induce the psoriasis model on mice ear.
The IL-1 family member IL-36 consists of 3 agonists and 1 antagonist; IL-36 α, IL-36β, and IL-36γ and the receptor antagonist IL-36Ra, respectively. Psoriatic epidermis expresses them except IL-36β. In addition, it has been suggested that the IL-36 pathway plays an important role in innate immunity during psoriasis development, since mice overexpressing IL-36 along with deletion of IL-36Ra gene exhibited a severe psoriatic phenotype. We previously demonstrated that IL-36R KO completely abolished the development of psoriatic inflammation in K5.Stat3C mice.
soriasis is one of major inflammatory skin diseases. TNF α, interleukin-17A (IL-17A) and IL-23 are deeply involved in the pathogenesis of psoriasis, and therapies targeted for each of these cytokines are highly effective. IL-33, a member of IL-1 family and the ligand of IL-1 receptor like 1 (ST2L), is expressed in the nucleus of epidermal keratinocytes i n the lesional skin of psoriasis, however, its involvement in the pathogenesis of psoriasis is unknown. ST2L, the receptor of IL-33, is expressed in many immune cells, such as T helper 2 (Th2) cells, macrophages and mast cells.